Albany Medical College is a medical school located in Albany, New York, United States. It was founded in 1839 by Alden March and James H. Armsby and is one of the oldest medical schools in the nation. The college is part of the Albany Medical Center, which includes the Albany Medical Center Hospital.Along with Albany College of Pharmacy, Albany Law School, the Dudley Observatory, the Graduate College of Union University, and Union College, it is one of the constituent entities of Union University.Over its 170 year history, Albany Medical College has attracted and produced many leaders in medicine and research. Among its present and past faculty, researchers, and alumni count two Nobel Prize winners, two Lasker Award winners, two MacArthur Fellowship recipients, one Gairdner Foundation International Award winner, former Surgeon General of the United States Army, former Surgeon General of the United States Air Force, several presidents and CEOs of major academic hospitals, as well as an early president and co-founder of the American Medical Association. AMC is attributed as the site where David S. Sheridan perfected the modern-day disposable catheter, among other major discoveries and innovations. Among AMC alumni accomplishments include the discovery of the hormone leptin, the invention of computed tomography, and the discovery of oral rehydration therapy. Wikipedia.
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Kremer J.M.,Albany Medical College
Arthritis and rheumatism
To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy. In this 24-week, double-blind, phase IIb study, patients with active RA (n = 507) were randomized to receive placebo or tofacitinib (20 mg/day, 1 mg twice daily, 3 mg twice daily, 5 mg twice daily, 10 mg twice daily, or 15 mg twice daily). All patients continued to receive a stable dosage of MTX. The primary end point was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. At week 12, ACR20 response rates for patients receiving all tofacitinib dosages ≥3 mg twice daily (52.9% for 3 mg twice daily, 50.7% for 5 mg twice daily, 58.1% for 10 mg twice daily, 56.0% for 15 mg twice daily, and 53.8% for 20 mg/day) were significantly (P ≤ 0.05) greater than those for placebo (33.3%). Improvements were sustained at week 24 for the ACR20, ACR50, and ACR70 responses, scores for the Health Assessment Questionnaire disability index, the 3-variable Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP), and a 3-variable DAS28-CRP of <2.6. The most common treatment-emergent adverse events occurring in >10% of patients in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 patients (4.1%) experienced serious adverse events. Sporadic increases in transaminase levels, increases in cholesterol and serum creatinine levels, and decreases in neutrophil and hemoglobin levels were observed. In patients with active RA in whom the response to MTX has been inadequate, the addition of tofacitinib at a dosage ≥3 mg twice daily showed sustained efficacy and a manageable safety profile over 24 weeks. Copyright © 2012 by the American College of Rheumatology. Source
Albany Medical College | Date: 2013-01-22
Establishment of an effective and uniform vaccine development strategy is key to conquering current and emerging infectious diseases. Despite successes against an array of bacterial agents, current approaches to vaccine development are as diverse as the microbes they target and require adjuvants that often have limited efficacy and/or toxic side effects. As a consequence, vaccine discovery is often slow, inefficient, and unsuccessful in the case of many high priority pathogens. The present disclosure suggests that vaccine generation for bacterial pathogens can be improved by optimizing the efficiency of processing/presentation of a bacterial immunogen via the targeting of immunogen to CR2 and/or TLR2 on APCs. This approach not only yields an adjuvant-free mucosal vaccine against a Category A biothreat agent, but also establishes a novel genetic approach/platform for vaccine development, which is applicable to many other infectious agents, thereby profoundly impacting preventive medicine/public health.
Albany Medical College | Date: 2013-03-25
A method of preventing drug use relapse by administering an effective amount of an 34 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use. A method of preventing drug use relapse due to cue inducement by administering an effective amount of an 34 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement. A method of preventing drug use relapse due to cue inducement by modulating the dopaminergic mesolimbic pathway by blocking 34 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala of a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement. A method of preventing drug use relapse by preventing a relapse of drug use during cue inducement.
Albany Medical College and Regenerative Research Foundation | Date: 2013-11-12
The present invention relates to treatment methods and methods for sustained delivery of one or more exogenous factors to desired nervous system sites. In certain embodiments, the invention relates to the use of biodegradable microspheres to deliver exogenous factors, such as the morphogenic factor, sonic hedgehog (Shh), to the site of spinal cord injury. In certain embodiments, the Shh-releasing microspheres are administered together with stem cells, which may be spinal cord neural stem cells. In certain embodiments, the invention relates to regrowth of neural cells in both the central and peripheral nervous systems.
Albany Medical College | Date: 2015-03-20
A method for correcting a spinal deformity is provided. A spinal implant for correcting a spinal deformity includes a multipoint connector that connects to at least one vertebra of a spine at a plurality of locations and a force directing device that applies a force to the vertebra through the multipoint connector. The force directing device may include a rod which extends generally along an axis of the spine and a force directing member which is adjustably coupled to both the rod and the multipoint connector and which applies a corrective force to the at least one vertebra.